Acute myelogenous leukemia (AML) is an aggressive hematologic cancer characterized by
infiltration of proliferative, clonal, abnormally differentiated cells of myeloid lineage in the …

Background Although the importance of the hematopoietic transcription factor PU. 1 in acute
myeloid leukemia (AML) has been demonstrated, the expression of PU. 1 in acute …

Mixed lineage leukemia (MLL) fusion proteins directly activate the expression of key
downstream genes such as MEIS1, HOXA9 to drive an aggressive form of human leukemia …

Background Transcription factor PU. 1, a member of the ETS family, is a master regulator of
myeloid differentiation whose functional disruption is often associated with acute myeloid …

PU. 1 is a key transcription factor for hematopoiesis and the reduction of this protein
expression plays important roles in various hematological malignancies. To identify PU. 1 …

Alterations of the transcription factors CCAAT/enhancer binding protein alpha (CEBPA) and
PU. 1 have been described in acute myeloid leukemia (AML). We studied CEBPA and PU. 1 …

The transcriptional activity of transcription factors is regulated by phosphorylation. The
uncontrolled expression and constitutive activation of transcriptional regulators have been …

Investigating the etiological causes of acute myeloid leukemia (AML) at the molecular level
should help in identifying targets and strategies that would increase the efficacy of the …

PU. 1 is an Ets family transcription factor that is required for the development of myeloid and
lymphoid cells. Since PU. 1 is required for several different lineages it has been unclear …

Improved understanding of the molecular pathways that suppress the genesis and
maintenance of cancer stem cells will facilitate development of rationally targeted therapies …